ethyl 4-(benzo[d]thiazol-2-ylamino)benzoate | 201410-56-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 4-(benzo[d]thiazol-2-ylamino)benzoate
• 英文别名: Ethyl 4-(2-benzothiazolylamino)benzoate；ethyl 4-(1,3-benzothiazol-2-ylamino)benzoate
• CAS: 201410-56-2
• 化学式: C₁₆H₁₄N₂O₂S
• 分子量: 298.365
• InChiKey: OSKZPWWOTKQCBD-UHFFFAOYSA-N

物化性质

• 沸点：
  453.8±47.0 °C(Predicted)
• 密度：
  1.316±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  79.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 4-(benzo[d]thiazol-2-ylamino)benzoate 在 lithium hydroxide 、 水 、 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 16.0h， 以1.19 g的产率得到4-(benzo[d]thiazol-2-ylamino)benzoic acid
  参考文献：
  名称：

  Selectively Targeting T- and B-Cell Lymphomas: A Benzothiazole Antagonist of α₄β₁ Integrin

  摘要：

  Current cancer chemotherapeutic agents clinically deployed today are designed to be indiscriminately cytotoxic, however. achieving selective targeting of cancer malignancies would allow for improved diagnostic and chemotherapeutic tools. Integrin alpha(4)beta(1), a heterodimeric cell surface receptor, is believed to have a low-affinity conformation in resting normal lymphocytes and an activated high-affinity conformation in cancerous cells, specifically T- and B-cell lymphomas. This highly attractive yet poorly understood receptor has been selectively targeted with the bisaryl urea peptidomimetic antagonist 1. However. concerns regarding its preliminary pharmacokinetic (PK) profile provided an impetus to change the pharmacophore from a bisaryl urea to a 2-arylaminobenzothiazole moiety, resulting in an analogue with improved physicochemical properties, solubility, and kidney:tumor ratio while maintaining potency (6; IC50 = 53 pM). The results presented herein utilized heterocyclic and solid-phase chemistry, cell adhesion assay, and in vivo optical imaging using the cyanine dye Cy5.5 conjugate.

  DOI：

  10.1021/jm800313f
• 作为产物：
  描述：

  4-(N'-phenyl-thioureido)-benzoic acid ethyl ester 在 氯仿 、 溴 作用下， 生成 ethyl 4-(benzo[d]thiazol-2-ylamino)benzoate
  参考文献：
  名称：

  Farooq; Hunter, Journal of the Indian Chemical Society, 1933, vol. 10, p. 563,568

  摘要：

  DOI：

文献信息

• N-[4-(Heteroarylmethyl)phenyl]-heteroarylamines
  申请人：Janssen-Cilag S.A.

  公开号：US06124330A1

  公开（公告）日：2000-09-26

  The present invention is concerned with compounds of formula ##STR1## the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein R.sup.1 is hydrogen, hydroxy, C.sub.1-6 alkyl or aryl; R.sup.2 is hydrogen; optionally substituted C.sub.1-12 alkyl; C.sub.3-7 cycloalkyl; C.sub.2-8 alkenyl, optionally substituted pyrrolidinyl or aryl; R.sup.3 is hydrogen, optionally substituted C.sub.1-6 alkyl or aryl; Het is an optionally substituted unsaturated heterocycle selected from imidazolyl, triazolyl, tetrazolyl and pyridinyl; ##STR2## is an optionally substituted unsaturated mono- or bicyclic heterocycle; and aryl is optionally substituted phenyl. The present invention also relates to processes for their preparation and compositions comprising said new compounds, as well as their use as a medicine.

  本发明涉及以下结构的化合物：##STR1## 其N-氧化物、药学上可接受的加合盐及其立体化异构体形式，其中R.sup.1为氢、羟基、C.sub.1-6烷基或芳基；R.sup.2为氢；可选择取代的C.sub.1-12烷基；C.sub.3-7环烷基；C.sub.2-8烯基，可选择取代的吡咯烷基或芳基；R.sup.3为氢，可选择取代的C.sub.1-6烷基或芳基；Het为从咪唑基、三唑基、四唑基和吡啶基中选择的可选择取代的不饱和杂环；##STR2## 为可选择取代的不饱和单环或双环杂环；芳基为可选择取代的苯基。本发明还涉及其制备方法和包含所述新化合物的组合物，以及它们作为药物的用途。
• Electrochemical NaI/NaCl-mediated one-pot synthesis of 2-aminobenzoxazoles in aqueous media<i>via</i>tandem addition–cyclization
  作者：Thao Nguyen Thanh Huynh、Theeranon Tankam、Shinichi Koguchi、Tanawat Rerkrachaneekorn、Mongkol Sukwattanasinitt、Sumrit Wacharasindhu

  DOI：10.1039/d1gc01131f

  日期：——

  An electrochemical synthesis of 2-aminobenzoxazoles from 2-aminophenols and isothiocyanates was successfully developed in a one-pot fashion. Using inexpensive and widely available NaI and NaCl co-operatively in catalytic amounts, our electrosynthesis approach provided various 2-aminobenzoxazole products in moderate to high yields in an open-flask type undivided cell without using any external supporting

  以一锅法成功开发了由 2-氨基苯酚和异硫氰酸酯电化学合成 2-氨基苯并恶唑。我们的电合成方法以催化量合作使用廉价且广泛可用的 NaI 和 NaCl，在不使用任何外部支持电解质和碱的情况下，在开放式烧瓶型未分隔电池中以中等至高产率提供各种 2-氨基苯并恶唑产品。该协议可用于以中等产率从相应的 2-苯硫酚合成 2-氨基苯并噻唑。该协议有很多好处。它不含金属且具有高度可扩展性，并在温和条件下使用廉价的介质和乙醇/水作为环保溶剂。
• [EN] N-[4-(HETEROARYLMETHYL)PHENYL]-HETEROARYLAMINES<br/>[FR] N-[4-(HETEROARYLMETHYL)PHENYL]-HETEROARYLAMINES
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：WO1997049704A1

  公开（公告）日：1997-12-31

  (EN) The present invention is concerned with compounds of formula (I), the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein R1 is hydrogen, hydroxy, C1-6alkyl or aryl; R2 is hydrogen; optionally substituted C1-12alkyl; C3-7cycloalkyl; C2-8alkenyl, optionally substituted pyrrolidinyl or aryl; R3 is hydrogen, optionally substituted C1-6alkyl or aryl; Het is an optionally substituted unsaturated heterocycle selected from imidazolyl, triazolyl, tetrazolyl and pyridinyl; formula (1) is an optionally substituted unsaturated mono- or bicyclic heterocycle; and aryl is optionally substituted phenyl. The present invention also relates to processes for their preparation and compositions comprising said new compounds, as well as their use as a medicine.(FR) L'invention concerne les composés présentant la formule (I), les N-oxydes, les sels additifs pharmaceutiquement acceptables et les formes stéréochimiquement isomères de ces composés. Dans la formule, R1 représente hydrogène, hydroxy, alkyle C1-6 ou aryle; R2 représente hydrogène, alkyle C1-12 éventuellement substitué, cycloalkyle C3-7; alcényle C2-8, pyrrolidinyle éventuellement substitué ou aryle; R3 représente hydrogène, alkyle C1-6 éventuellement substitué ou aryle. Het représente un hétérocycle non saturé éventuellement substitué sélectionné parmi l'imidazolyle, triazolyle, tétrazolyle et pyridinyle; la formule (1) est un hétéroxycle mono- ou bicyclique non saturé éventuellement substitué et aryle est phényle éventuellement substitué. L'invention concerne des procédés pour la préparation de ces composés et des compositions les comprenant ainsi que leur utilisation comme médicaments.

  本发明涉及公式（I）的化合物，其N-氧化物，药学上可接受的加成盐和立体化学异构体形式，其中R1是氢，羟基，C1-6烷基或芳基; R2是氢; 可选取代的C1-12烷基; C3-7环烷基; C2-8烯基，可选取代的吡咯烷基或芳基; R3是氢，可选取代的C1-6烷基或芳基; Het是从咪唑基，三唑基，四唑基和吡啶基中选取的可选取代的不饱和杂环; 公式（1）是可选取代的不饱和单环或双环杂环; 芳基是可选取代的苯基。本发明还涉及其制备方法和包含所述新化合物的组合物，以及它们作为药物的用途。
• N-[4-(heteroarylmethyl)phenyl]-heteroarylamines
  申请人：——

  公开号：US20030176419A1

  公开（公告）日：2003-09-18

  The present invention is concerned with compounds of formula 1 the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein R 1 is hydrogen, hydroxy, C 1-6 alkyl or aryl; R 2 is hydrogen; optionally substituted C 1-12 alkyl; C 3-7 cycloalkyl; C 2-8 alkenyl, optionally substituted pyrrolidinyl or aryl; R 3 is hydrogen, optionally substituted C 1-6 alklyl or aryl; Het is an optionally substituted unsaturated heterocycle selected from imidazolyl, triazolyl, tetrazolyl and pyridinyl; 2 is an optionally substituted unsaturated mono- or bicyclic heterocycle; and aryl is optionally substituted phenyl. The present invention also relates to processes for their preparation and compositions comprising said new compounds, as well as their use as a medicine.

  本发明涉及公式1的化合物，其N-氧化物，药学上可接受的加成盐和立体化学异构体形式，其中R1为氢，羟基，C1-6烷基或芳基；R2为氢；可选取代的C1-12烷基；C3-7环烷基；C2-8烯基，可选取代的吡咯烷基或芳基；R3为氢，可选取代的C1-6烷基或芳基；Het为可选取代的未饱和杂环，选自咪唑基，三唑基，四唑基和吡啶基；2为可选取代的未饱和单环或双环杂环；芳基为可选取代的苯基。本发明还涉及其制备方法和包含上述新化合物的组合物，以及它们作为药物的用途。
• N-&lsqb;4-(heteroarylmethyl)phenyl&rsqb;-heteroarylamines
  申请人：Janssen Pharmaceutica N.V.

  公开号：US06486187B1

  公开（公告）日：2002-11-26

  The present invention is concerned with compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein R1 is hydrogen, hydroxy, C1-6alkyl or aryl; R2 is hydrogen; optionally substituted C1-12alkyl; C3-7cycloalkyl; C2-8alkenyl, optionally substituted pyrrolidinyl or aryl; R3 is hydrogen, optionally substituted C1-6alkyl or aryl; Het is an optionally substituted unsaturated heterocycle selected from imidazolyl, triazolyl, tetrazolyl and pyridinyl; is an optionally substituted unsaturated mono- or bicyclic heterocycle; and aryl is optionally substituted phenyl. The present invention also relates to processes for their preparation and compositions comprising said new compounds, as well as their use as a medicine.

  本发明涉及公式N-氧化物化合物，其药学上可接受的加合盐和立体化学异构体形式，其中R1为氢、羟基、C1-6烷基或芳基；R2为氢；可选取代的C1-12烷基；C3-7环烷基；C2-8烯基，可选取代的吡咯烷基或芳基；R3为氢、可选取代的C1-6烷基或芳基；Het为可选取代的未饱和杂环，选自咪唑基、三唑基、四唑基和吡啶基；是可选取代的未饱和单环或双环杂环；芳基为可选取代的苯基。本发明还涉及它们的制备方法和包含所述新化合物的组合物，以及它们作为药物的用途。